3 results
Approved WMOCompleted
To assess the bioequivalence of 6 mg dexamethasone tablet administered PO as an alternative to 5,26 mg dexamethasone-disodiumphosphate (= 4 mg dexamethasone) solution administered IV
Approved WMOCompleted
The goal of this study is to prove whether kidney transplant recipients can reduce their risk of cardiovascular disease bij converting to Nulojix.
Approved WMORecruiting
The purpose of the study is to provide ongoing post-market demonstration of the safety and performance of the FARAPULSEPulsed Field Ablation System in the treatment of patients with paroxysmal atrial fibrillation (PAF).